Ratios Uncovered: Breaking Down Akebia Therapeutics Inc. (AKBA)’s Trailing Twelve Months Metrics

Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The price of Akebia Therapeutics Inc. (NASDAQ: AKBA) closed at $1.06 in the last session, down -0.93% from day before closing price of $1.07. In other words, the price has decreased by -$0.93 from its previous closing price. On the day, 1.25 million shares were traded. AKBA stock price reached its highest trading level at $1.0976 during the session, while it also had its lowest trading level at $1.05.

Ratios:

We take a closer look at AKBA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.31 and its Current Ratio is at 1.70.

On August 28, 2023, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $3.75.

Piper Sandler Upgraded its Neutral to Overweight on May 31, 2023, whereas the target price for the stock was revised from $2 to $4.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 13 ’24 when Dahan Michel sold 34,840 shares for $1.26 per share. The transaction valued at 43,898 led to the insider holds 672,092 shares of the business.

Hadas Nicole R. sold 12,016 shares of AKBA for $15,140 on May 13 ’24. The SVP, Chief Legal Officer now owns 651,243 shares after completing the transaction at $1.26 per share. On Feb 29 ’24, another insider, Butler John P., who serves as the CEO and President of the company, sold 46,570 shares for $1.58 each. As a result, the insider received 73,581 and left with 2,044,580 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 222171744 and an Enterprise Value of 278555168. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.19. Its current Enterprise Value per Revenue stands at 1.488 whereas that against EBITDA is 70.236.

Stock Price History:

Over the past 52 weeks, AKBA has reached a high of $2.48, while it has fallen to a 52-week low of $0.78. The 50-Day Moving Average of the stock is -20.55%, while the 200-Day Moving Average is calculated to be -18.27%.

Shares Statistics:

According to the various share statistics, AKBA traded on average about 5.01M shares per day over the past 3-months and 2163520 shares per day over the past 10 days. A total of 194.58M shares are outstanding, with a floating share count of 192.27M. Insiders hold about 8.27% of the company’s shares, while institutions hold 20.89% stake in the company. Shares short for AKBA as of 1715731200 were 11698707 with a Short Ratio of 2.33, compared to 1713139200 on 13689136. Therefore, it implies a Short% of Shares Outstanding of 11698707 and a Short% of Float of 5.6399997.

Most Popular